Podcasts about Lymphoma

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Haris Sohail and Lucas Kühne on their latest articles published in volume 147 issue 21 of Blood. In this CME article titled, "Retrospective, Real-World Study of IV Iron Use to Treat Iron deficiency Anemia During Acute Infection",  Sohail et al show that IV iron given during acute infection with iron deficiency anemia is associated with improved 14-day and 90-day survival as well as hemoglobin recovery. Although this report has the limitations of a retrospective study, these findings challenge current practice and support randomized trials that include patients with infection. In "Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Purpura", Kühne et al show in a multicenter registry study of 204 patients that refractoriness during caplacizumab treatment in immune TTP is uncommon and, when observed, is typically associated with confounding clinical factors. These findings underscore the importance of careful clinical reassessment and evaluation for alternative etiologies in patients with delayed platelet recovery, rather than attributing such cases to true treatment resistance.

What if the way back to health isn't found in fighting harder… but in reconnecting with nature? After being diagnosed with leukemia and lymphoma, Dean Hall made a decision that left even his doctors shaking their heads. He swam 187 miles of Oregon's longest river. He embraced a practice known as forest bathing. Today, Dean is in remission! Coincidence? Conviction? Or is there more to this story? In this week's episode, Autumn and Dean explore a radically different conversation about healing, purpose, grief, the nervous system, and our relationship with the natural world God created. This conversation may completely change the way you think about striving for health, supporting the body's ability to heal, and God's fingerprints woven throughout creation.

In this episode of the Oncology Brothers podcast, we tackled two real-world challenging cases in diffuse large B-cell lymphoma (DLBCL) alongside two lymphoma experts — Dr. Matthew Lunning from the University of Nebraska and Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. The central question: when faced with relapsed or transformed aggressive B-cell lymphoma, how do you choose between CAR-T cell therapy and bispecific antibodies, and how do you get patients through this safely?   Key topics discussed included: The role of CAR-T cell therapy in early relapsed DLBCL based on ZUMA-7 and TRANSFORM trial data, and practical strategies for bridging and holding therapy pre- and post-apheresis to safely deliver treatment. A comparison of axicabtagene ciloleucel versus lisocabtagene maraleucel in terms of efficacy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) rates, and outpatient feasibility. Management of transformed follicular lymphoma to double-hit DLBCL in the third-line setting, including the role of glofitamab, mosunetuzumab, polatuzumab, and epcoritamab as bridges to CAR-T cell therapy. The importance of early partnership between community oncologists and tertiary care centers to ensure patients access CAR-T and bispecific therapies in a timely manner. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Join us for this expert discussion on navigating the complex treatment landscape of relapsed and transformed aggressive B-cell lymphoma. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #DLBCL, #CARTTherapy, #BispecificAntibodies, #Hematology, #OncologyBrothers  

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Kirsty Hillier and Marco Ruella on their latest articles published in Blood. For "Predicting Development of Pediatric Chronic Immune Thrombocytopenia at Disease Onset Using a Statistical Risk Model", Dr. Hillier shares the potential benefits of incorporating this new model to enhance the care of the 1 in 4 patients who develop chronic ITP. As an alternative to current guidelines which advise providers to "wait and see", this online model determines patients who are at risk for chronic ITP, allowing for providers to make informed decisions on their continued care. In "Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies", Dr. Ruella explains how the treatment of T-cell neoplasms is limited by a lack of discriminating T-cell antigens that allow for effective antitumor responses while preventing CAR T-cell fratricide. The team found that CD2 was a viable target, especially combined with a novel PD-1:CD2 switch receptor to remedy dysfunction caused by CD2 deletion.  

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Carla Casulo, a world-renowned clinician and researcher from the University of Rochester, to discuss the latest highlights from the European Hematology Association (EHA) 2026 conference, focusing on lymphoma.   Join us as we dived into four pivotal studies: frontMIND: We explored the efficacy of tafasitamab plus lenalidomide with R-CHOP compared to R-CHOP alone in frontline treatment for diffuse large B-cell lymphoma (DLBCL). Discover the implications of improved progression-free survival (PFS) and the associated toxicities. POLAR-BEAR: We discussed the head-to-head comparison of mini–pola-R-CHP versus mini–R-CHOP in frail or elderly patients with DLBCL. What does this mean for the use of polatuzumab in clinical practice? High-Dose Methotrexate for CNS Prophylaxis: Learn about the significant findings that suggest high-dose methotrexate may not improve outcomes in high-risk patients, potentially changing treatment protocols. EPCOR FL1: We covered the approval of epcoritamab in relapsed and refractory follicular lymphoma, highlighting its benefits and the importance of time-limited therapy.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Tune in for an insightful discussion on these important studies and their potential impact on clinical practice. Don't forget to subscribe for more updates on conference highlights, FDA approvals, and treatment algorithms!

In our latest podcast, Professor Andy Davies, Professor of Haematological Oncology at the University of Southampton and Dr Cathy Burton, Consultant Haematologist at Leeds Teaching Hospital talk to Lymphoma Action's Anne Hook. They talk about how lymphoma management has changed over the past 40 years and discuss how lymphoma treatment and care may look in the future. Forty years ago, the diagnosis of lymphoma was much simpler, with high-grade, low-grade and Hodgkin lymphoma being the main entities. Since the 1980s, techniques have developed to enable more accurate diagnoses and a greater understanding of lymphoma biology. Today, instead of three main types of lymphoma, there are over 100 different subtypes. This means that instead of the blunt approach to treatment 40 years ago where ‘one size fits all', clinicians today are able to deliver more individualised treatment. Andy Davies and Cathy Burton talk about the introduction of the monoclonal antibody rituximab in the 1990s, which has had a major impact. In the podcast they also talk about improvements in cellular therapies, resulting in improvements in transplantation and the introduction of CAR-T cell therapy for some types of lymphoma. Looking to the future, bispecific antibodies and targeted therapies will help improve effectiveness while minimising toxicity and provide the opportunity for different approaches to treatment delivery.Lymphoma Voices is a series of podcasts for people living with lymphoma, and their family and friends. In each podcast, we are in conversation with an expert in their field, or someone who has been personally affected by lymphoma, who shares their thoughts and experiences. Lymphoma Action is the only charity in the UK dedicated to supporting people affected by lymphoma. We are here to make sure that everyone affected by the condition receives the best possible information, support, treatment and care. Our services include a Freephone helpline, support group network, Buddy Service, medical information, conferences for those affected by lymphoma, and education and training for healthcare professionals. We would like to thank all of our incredible supporters whose generous donations enable us to offer all our essential support services free of charge. As an organisation we do not receive any government or NHS funding and so every penny received is truly valued. From everyone at Lymphoma Action and on behalf of those affected by lymphoma, thank you. For further information visit: www.lymphoma-action.org.uk

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Heinz Zoller and Raul Ribeiro on their latest articles published in Blood. Dr. Zoller discusses "Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia", and how these findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications.  Dr. Ribeiro discusses "A low-versus standard-dose regimen an induction for AML: a multicenter, randomized noninferiority trial" and how the low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings.

Send us Fan MailSteve Olsen is a retired dentist, a high-performance coach, and a walking miracle. Diagnosed simultaneously with stage four lymphoma, stage one kidney cancer, and total kidney failure requiring dialysis, Steve was handed a grim medical prognosis. Refusing to accept the “probable,” he relentlessly focused on the “possible”. By combining traditional medical interventions with advanced mindset techniques, NuCalm neuroacoustic technology, and deep faith, Steve achieved complete remission within a year. Today, through his platform OptimalPerformance.cc, he coaches everyone from patients to race car drivers on how to control their thoughts, enter the flow state, and live a life of victory.Key Discussion Highlights & TakeawaysThe Cancer Diagnosis: How Steve processed the devastating news of stage 4 lymphoma and kidney failure, and why he immediately rejected the standard terminal timeline.Possible vs. Probable: The crucial mindset shift required to survive critical illness, and why Steve tells patients to actively seek out stories of people who beat the odds.The NuCalm Protocol: How Steve used binaural beats and the NuCalm system to safely guide his brain into the Gamma flow state, allowing him to visualize his immune system destroying cancer cells.Respond, Don't React: Why reacting is an emotion-driven survival reflex, whereas responding is a deliberate, calm, and practiced choice that lowers the body's toxic stress load.The Black Door: A powerful illustration of why human beings often choose the comfort of known suffering over the fear of the unknown—even when the unknown leads to freedom Key Timestamps & Moments of Gold00:00:00 – Episode Intro & MyPillow Mega Sale00:02:40 – Welcome Steve Olsen: The Importance of Mindset00:05:00 – Steve's Early Life, Photojournalism, and Coaching Roots00:09:10 – Facing Stage 4 Lymphoma, Kidney Cancer, and Dialysis00:13:30 – Fixed vs. Growth Mindset and the Power of Definition00:15:10 – The Bernie Siegel Story: How Words Can Kill or Heal00:20:40 – The Gamma Brain Wave: Visualizing Healing and Flow State00:23:00 – Using NuCalm to Warp Time Perception and Relieve Stress00:30:20 – Stress: The Silent Killer and the “Respond vs. React” Framework00:35:00 – Victor Frankl and Choosing Your Response in the Darkest Times00:38:00 – Rebuilding Concrete Hope When All Seems Lost00:44:00 – Entering the Gamma State Safely with Binaural Beats00:50:00 – Connecting with Steve Olsen at optimalperformance.cc00:54:00 – Final Thoughts, Taking Action, and Episode Wrap-UpWebsite: https://OptimalPerformance.cc (not .com)More Info: https://www.copingconqueringcancer.comSupport the showTHE NOT-SO-FINE-PRINT DISCLAIMER: While we are very thankful for all of our guests, please understand that we do not necessarily share or endorse the same beliefs, worldviews, or positions that they may hold. We respectfully agree to disagree in some areas, and thank God for the blessing and privilege of free will.For more Remarkable Episodes, Inspiration, and Motivation, please visit https://davidpasqualone.com/remarkable-people-podcast/ now!

This week we welcome the boy Foster Moreau back to the pod, and it's safe to say Foster has had one of the craziest offseasons of all NFL Players. The boys immediately get some hot takes about some actor as well as get into some conspiracy theories. Foster shares some stories of his time at LSU about different bars he used to go to and just the town itself. The boys then get into Foster’s crazy offseason. He was diagnosed with Hodgkin's Lymphoma in March while on a visit to the Saints. He shares the story of how he found out from his physical and the exact type of cancer he was diagnosed with. Foster gets into what it was like telling his family and friends and how difficult it was. The boys then lighten the mood as they get into how he has officially been signed to the New Orleans Saints and is reunited with Derek Carr. The boys end the pod with a legendary Tier Talk of best iPhone games. Foster was super open with the boys and it is no doubt a must listen. Enjoy.See omnystudio.com/listener for privacy information.

EVEN MORE about this episode!Join Julie Ryan for another inspiring live episode as callers from around the world seek answers about chronic health conditions, grief, anxiety, family relationships, and spiritual guidance.Julie performs real-time medical intuitive scans for concerns including hormone imbalances, inflammation, eczema, pancreatic cancer recovery, neuropathy, back injuries, macular degeneration, and mold sensitivity while offering practical wellness suggestions and energetic healing. Along the way, she shares actionable insights on nutrition, supplements, bioidentical hormones, and supporting the body's natural healing abilities.The episode also features touching spirit communication, including a heartfelt message from a caller's late girlfriend and powerful guidance for navigating loss, family estrangement, and emotional healing. Whether you're searching for health answers, spiritual comfort, or a deeper understanding of your body's wisdom, this episode offers hope, healing, and practical guidance you can apply to your own life.Episode Chapters:(0:02:42) - Helen from England: Family Estrangement and Telepathic Communication(0:05:19) - Greg from Atlanta: Connecting with His Deceased Girlfriend Karen(0:14:10) - Nina from New Jersey: Body Scan for Inflammation, Hormones, and Weight(0:19:18) - Nancy from Oklahoma City: Eczema, Leaky Gut, and Yeast Overgrowth(0:23:21) - Eileen from New Jersey: Squirrel Incident, Bulging Disc, and Osteoporosis(0:33:08) - Mary from Florida: Pancreatic Cancer Recovery and Neuropathy Healing(0:44:27) - Karen from Chicago: Healing for Husband Mark's Non-Hodgkin's Lymphoma(0:50:14) - Medical Intuitive Training Class Winner(0:54:00) - Sarah: How to Go Within, Meditate, and Ground(0:57:13) - Yohannes from Cambridge: Healing for His Mother's Macular Degeneration(1:04:56) - Azura from Tulum: Mold Sensitivity and Finding Safe Housing➡️ Subscribe to Ask Julie Ryan YouTube➡️ Julie's Intuitive Trainings✏️ Ask Julie a Question!

Jonathon Cohen, MD, MS When you hear the word “aggressive,” it can feel overwhelming, but in diffuse large B-cell lymphoma (DLBCL), it can also point to something encouraging – a potential cure. In this episode, we speak with Dr. Jonathon Cohen, of Winship Cancer Institute in Atlanta, GA, about what a DLBCL diagnosis really means, from how this common type of non-Hodgkin lymphoma is identified to current treatment options and emerging therapies. We explain what patients and families need to know about side effects. We also look at new treatments, including CAR T-cell therapy and bispecific antibodies, and the importance of open communication with your care team. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Diffuse large B-cell lymphoma CAR T-cell therapy Stem cell transplantation Bispecific antibodies (immunotherapy fact sheet) Clinical Trial Support Center Additional Blood Cancer United Support Resources: Information Specialists Young Adult Resources Young Adult Online Chat Financial support Free Nutrition Consultations Free telephone/web patient programs SHARE web series Online videos Free booklets Patient Community Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Mental Health Resources Episode supported by Genmab US, Inc.The post Diffuse Large B-Cell Lymphoma (DLBCL): Breaking Down an Aggressive Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.

In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Everett Meyer and Olivier Hermine on their latest articles published in volume 147 issue 11 of Blood. Dr. Everett Meyer discusses "Orca-T vs allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial" which demonstrated that Orca-T showed superior chronic GVHD–free survival compared to the control arm (78.0% vs 38.4%, P < .001) and lower nonrelapse mortality (3.4% vs 13.2%, P = .03). Dr. Olivier Hermine shares insights from "VEXAS anemia is a mosaic erythroblastopenia" which proposes that VEXAS syndrome–associated anemia should be considered as a mosaic erythroblastopenia, in which the severity of anemia is influenced by the quality and quantity of the UBA1–wild-type compartment.

The Alarm's final album Transformation came out May 29th, The album was made by beloved artist and musician, Mike Peters while he was in treatment for the cancer that ultimately took him. “Mike lived a life of beauty and never gave up right to the very end,” says Jules Peters, bandmate and wife.Described by Bono of U2 as “the second greatest rock and roll band in the world,” Mike Peters has been the driving force behind The Alarm for over forty creative years of new music making and dedication to presenting the band's classic songs in ways both imaginative and inventive. A voice of defiance and hope both on and off the stage, Peters first rose to prominence in the early 1980s with The Alarm, whose powerful anthems like "68 Guns" and "Strength" helped define a generation of alternative rock. Known for their empowering anthems and heartfelt lyrics, The Alarm garnered a devoted international following, with Peters' raw vocals and commanding stage presence at the heart of it all, garnering number one rock album chart hits in the USA / UK and 4 albums in the top 10 with Equals, Sigma, Omega and Forwards. During a music career that spanned five decades, Peters performed with some of music's greatest artists and bands including Bob Dylan, Neil Young, Bruce Springsteen and U2.Diagnosed with lymphoma in 1995 and later with chronic lymphocytic leukemia, Peters refused to let his illness silence him. Instead, he turned his fight into a mission to help others.Alongside his wife Jules, he co-founded Love Hope Strength, a music-driven cancer charity that revolutionized awareness and action around stem cell donation that continues beyond his passing. Through its innovative “Get On The List” campaigns—often hosted at rock concerts and even atop mountains—the charity has added over 400,000 people to the global stem cell registry and helped secure thousands of potential life-saving matches for patients worldwide. While this may seem like the final chapter for The Alarm, Transformation promises that the legacy of The Alarm will transform into something larger. While Mike has gone out in a blaze of glory, his love, hope and strength continues on. Echoing the title of the new single, Jules concludes, “Mike and the spirit of The Alarm will ‘Live Today,' forever more. I invite you all to blast Transformation out loud. Imagine Mike in the room with you. Transformation is his battle cry, his resilient love of life. Right to the very end, Mike believed that he was going to live, to be totally free. My last memory is driving him open top along the North Wales coast road, playing Transformation at maximum volume. He was so happy. So full of life. Playing his air drums, bass guitar, already imagining himself on his next world tour. So keep that positive spirit moving forwards. Imagine him as you all knew him best, striding out on to that stage, changing lives one concert at a time. This is an album of hope and a passionate celebration of a life well lived. Please do not be sad. Mike wouldn't want that. He was so proud of this album and had the best time recording it during the last six months of his life. Blast it out loud like Mike did. Play along to the track list and most of all, be happy that we all had Mike in our lives and continue to do so. The music of Mike and The Alarm will always keep us strong”.Click Here to Subscribe to The Adventures of Pipeman for PERKS, BONUS Content & FREE GIVEWAYS! Take some zany and serious journeys with The Pipeman aka Dean K. Piper, CST on The Adventures of Pipeman also known as Pipeman Radio syndicated globally “Where Who Knows And Anything Goes.”   Would you like to be a sponsor of the show?Would you like to have your business, products, services, merch, programs, books, music or any other professional or artistic endeavors promoted on the show?Would you like to be interviewed as a professional or music guest on The Adventures of Pipeman, Positively Pipeman and/or Pipeman in the Pit?Would you like to host your own Radio Show, Streaming TV Show, or Podcast?  PipemanRadio Podcasts are heard on Pipeman Radio, Talk 4 Media, iHeartRadio, Pandora, Amazon Music, Audible, Spotify, Apple Podcasts, and over 100 other podcast outlets where you listen to Podcasts. The following are the different podcasts to Follow, Listen, Download, Subscribe:The Adventures of PipemanPipeman RadioPipeman in the Pit – Music Interviews & FestivalsPipeman – The Wandering JewPositively Pipeman – Empowerment, Inspiration, Motivation, Self-Help, Business, Spiritual & Health & WellnessClick Here to Subscribe for PERKS, BONUS Content & FREE GIVEWAYS!Follow @pipemanradio on all socials & Pipeman Radio Requests & Info at www.linktr.ee/pipemanradioStream The Adventures of Pipeman daily & live Mondays, Tuesdays, Wednesdays at 1PM ET on W4CY Radio & Talk 4 TV. Download, Rate & Review the Podcast at The Adventures of Pipeman, Pipeman Radio, Talk 4 Media, iHeartRadio, Apple Podcasts, YouTube & All Podcast Apps.

The Alarm's final album Transformation came out May 29th, The album was made by beloved artist and musician, Mike Peters while he was in treatment for the cancer that ultimately took him. “Mike lived a life of beauty and never gave up right to the very end,” says Jules Peters, bandmate and wife.Described by Bono of U2 as “the second greatest rock and roll band in the world,” Mike Peters has been the driving force behind The Alarm for over forty creative years of new music making and dedication to presenting the band's classic songs in ways both imaginative and inventive. A voice of defiance and hope both on and off the stage, Peters first rose to prominence in the early 1980s with The Alarm, whose powerful anthems like "68 Guns" and "Strength" helped define a generation of alternative rock. Known for their empowering anthems and heartfelt lyrics, The Alarm garnered a devoted international following, with Peters' raw vocals and commanding stage presence at the heart of it all, garnering number one rock album chart hits in the USA / UK and 4 albums in the top 10 with Equals, Sigma, Omega and Forwards. During a music career that spanned five decades, Peters performed with some of music's greatest artists and bands including Bob Dylan, Neil Young, Bruce Springsteen and U2.Diagnosed with lymphoma in 1995 and later with chronic lymphocytic leukemia, Peters refused to let his illness silence him. Instead, he turned his fight into a mission to help others.Alongside his wife Jules, he co-founded Love Hope Strength, a music-driven cancer charity that revolutionized awareness and action around stem cell donation that continues beyond his passing. Through its innovative “Get On The List” campaigns—often hosted at rock concerts and even atop mountains—the charity has added over 400,000 people to the global stem cell registry and helped secure thousands of potential life-saving matches for patients worldwide. While this may seem like the final chapter for The Alarm, Transformation promises that the legacy of The Alarm will transform into something larger. While Mike has gone out in a blaze of glory, his love, hope and strength continues on. Echoing the title of the new single, Jules concludes, “Mike and the spirit of The Alarm will ‘Live Today,' forever more. I invite you all to blast Transformation out loud. Imagine Mike in the room with you. Transformation is his battle cry, his resilient love of life. Right to the very end, Mike believed that he was going to live, to be totally free. My last memory is driving him open top along the North Wales coast road, playing Transformation at maximum volume. He was so happy. So full of life. Playing his air drums, bass guitar, already imagining himself on his next world tour. So keep that positive spirit moving forwards. Imagine him as you all knew him best, striding out on to that stage, changing lives one concert at a time. This is an album of hope and a passionate celebration of a life well lived. Please do not be sad. Mike wouldn't want that. He was so proud of this album and had the best time recording it during the last six months of his life. Blast it out loud like Mike did. Play along to the track list and most of all, be happy that we all had Mike in our lives and continue to do so. The music of Mike and The Alarm will always keep us strong”.Click Here to Subscribe to Pipeman in the Pit for PERKS, BONUS Content & FREE GIVEWAYS!  Pipeman in the Pit is a music, festival, and interview segment of The Adventures of Pipeman Radio Show (#pipemanradio) and from The King of All Festivals while on The Pipeman Radio Tour. Pipeman in the Pit features all kinds of music and interviews with bands & music artists especially in the genres of Heavy Metal, Rock, Hard Rock, Classic Rock, Punk Rock, Goth, Industrial, Alternative, Thrash Metal & Indie Music. Pipeman in the Pit also features press coverage of events, concerts, & music festivals.   Pipeman Productions is an artist management company that sponsors the show introducing new local & national talent showcasing new artists & indie artists.Then there is The Pipeman Radio Tour where Pipeman travels the country and world doing press coverage for Major Business Events, Conferences, Conventions, Music Festivals, Concerts, Award Shows, and Red Carpets. One of the top publicists in music has named Pipeman the “King of All Festivals.” So join the Pipeman as he brings “The Pipeman Radio Tour” to life right before your ears and eyes.Would you like to be a sponsor of the show?Would you like to have your business, products, services, merch, programs, books, music or any other professional or artistic endeavors promoted on the show?Would you like to be interviewed as a professional or music guest on The Adventures of Pipeman, Positively Pipeman and/or Pipeman in the Pit?Would you like to host your own Radio Show, Streaming TV Show, or Podcast?    PipemanRadio Podcasts are heard on Pipeman Radio, Talk 4 Media, iHeartRadio, Pandora, Amazon Music, Audible, Spotify, Apple Podcasts, and over 100 other podcast outlets where you listen to Podcasts.   The following are the different podcasts to Follow, Listen, Download, Subscribe:The Adventures of PipemanPipeman RadioPipeman in the Pit – Music Interviews & FestivalsPipeman – The Wandering JewPositively Pipeman – Empowerment, Inspiration, Motivation, Self-Help, Business, Spiritual & Health & WellnessBecome a supporter of this podcast: https://www.spreaker.com/podcast/pipeman-in-the-pit--2287932/support.Click Here to Subscribe for PERKS, BONUS Content & FREE GIVEWAYS!Follow @pipemanradio on all socials &  Pipeman Radio Requests & Info at www.linktr.ee/pipemanradioStream The Adventures of Pipeman daily & live Mondays, Tuesdays, Wednesdays at 1PM ET on W4CY Radio & Talk 4 TV. Download, Rate & Review the Podcast at The Adventures of Pipeman, Pipeman Radio, Talk 4 Media, iHeartRadio, Apple Podcasts, YouTube & All Podcast Apps.

During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York, US. Hosted on Acast. See acast.com/privacy for more information.

Drs. Tina Lockwood and Stacy Gray share the newly released evidence-based guideline on circulating tumor DNA (ctDNA) testing from ASCO. They highlight recommendations on when ctDNA testing should be offered—including scenarios where tissue biopsies are challenging, unsafe, or unavailable in time to guide management—and explicitly outline situations where testing should not be utilized. They dive into the evidence evaluating ctDNA for treatment selection, molecular residual disease (MRD), and response monitoring across solid tumors and lymphoma. Drs. Lockwood and Gray explain the importance of balancing ctDNA's high specificity with its moderate sensitivity. They also touch on outstanding questions, including standardizing definitions for MRD, disease-specific applications, and the use of multi-cancer early detection (MCED) screening.  Read the full guideline, "Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline" at www.asco.org/molecular-testing-and-biomarkers-guidelines" LINK TO FULL TRANSCRIPT

In this episode, Blood editor Dr. Laura Michaelis interviews Drs. Nigel Russell and Uwe Platzbecker on their articles published in volume 147 issue 10 of Blood. Dr. Russell discuses "CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial" where a large randomized trial demonstrated that DA-GO2 provided greater overall survival as compared to CPX-351, and that further studies should compare DA-GO2 to lower-intensity venetoclax-based regimens. Dr. Platzbecker shares insights from the first prospective study to evaluate the clinical impact of early therapeutic intervention for MRD in "Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial" demonstrating potential therapies for patients to achieve and maintain remission.

Welcome back to Proper True Yarn! Recorded LIVE at AlphaFest, this episode is packed with wild, hilarious and unbelievable crowd yarns. First up, Zak meets a drummer with one of the most cooked highway stories you'll ever hear, involving a dodgy Honda Accord and a very questionable driver. Then Chris shares an incredible survival story after being diagnosed with stage four Burkitt's lymphoma at just 15 years old. Given only 12 to 24 hours to live, he somehow pulled through, beat cancer and is now 25 years cancer free. We also hear a classic old-school motorbike yarn from Townie, before the Novocastrian Nuisance wraps things up with a parenting lesson gone horribly wrong involving hygiene advice, a young fella and a scourer. Funny, shocking, emotional and very Australian, this is AlphaFest Live at its finest.#propertrueyarn 

In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.

In 2008, Elaine Gibson was diagnosed with Stage IV Non-Hodgkin's Lymphoma and told she wouldn't live to see her grandchildren grow up. After experiencing this recurrence, she refused to accept that prognosis and turned to nature and the body's innate wisdom. Through Dr. Otto Warburg's research, she discovered how oxygen and cellular health are key to healing. While all the Radical Remission Healing Factors are part of her lifestyle, changing her diet, taking control of her health, and deepening her spiritual connection became the foundation of her healing journey. Today, Elaine is cancer-free and a green-juice-loving grandmother, and creator of the Starving Cell Recovery Method™.  Elaine now guides women to master a lifestyle that creates a body where cancer cannot grow, helping them live with energy, clarity, and peace of mind—without giving up chocolate—on and off the pickleball court. https://renewedlivinginc.com/ https://www.facebook.com/elaine.gibson.188; https://www.instagram.com/elaine_gibson_gaga/  Free Gift: https://renewedlivinginc.com/starving-cell-recovery-system-radical-remission/  _______ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To learn more about Radical Remission health coaching with Liz or Karla, Click Here   Join our mailing list and you'll receive our free eBook, Kickstart Your Healing: 20 Radical Remission Tips, as a special thank you for joining. Subscribe Here   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here. To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. Follow us on Social Media: Facebook  Instagram YouTube ______ Our Sponsor: Nestled in the pristine, natural beauty of British Columbia, The Healing Oasis stands as Canada's first-of-its-kind cancer wellness retreat, where hope reignites and the body is empowered to heal. Here, our renowned naturopathic cancer expert, Dr. Sean Ceaser, designs a fully personalized protocol of advanced, non-toxic therapies—including high-dose IVs like mistletoe and vitamin C, cutting-edge hyperthermia, PEMF, oxygen therapy, red light, and more. Savor daily organic, cancer-fighting meals, rest deeply in serene cabins, immerse in restorative activities like forest walks and yoga, drink mineral-rich living water, and receive emotional support in a peaceful sanctuary that combines world-class care with profound nature immersion to reduce side effects, boost vitality, and spark radical healing. Your journey to feeling alive again begins today at thehealingoasis.ca. Learn More about The Healing Oasis: Website   Testimonials Video Overview

Yah Welcome Wednesday It has been a question that's been hitting our inbox since we started and today we answer it, today we discuss the idea of welcoming a female voice on the show!... New Zealand has always been portrayed as a sporting country but is that really the case?... The Shifters are given a chance to ask us anything and well, we have to answer!... The Speights Men's Den is a powerful one, as Shift Nation. We have the opportunity to come together and help one of our own, Mike... Mike has been battling Non -Hodgkin's Lymphoma since March 2025 and is in need of treatment that requires him to go overseas but the thing is, it isn't cheap... Shift Nation let's do what we do best and come together to help, but the time to help Mike is now! (Link Below To Donate) Shift Nation, Any donations are more than appreciated! If you would like to donate to help Mike, tap the link below! https://givealittle.co.nz/cause/help-mikey-reach-his-car-t-therapy-overseas Hit that link below to stay caught up with anything and everything TMS. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.facebook.com/groups/3394787437503676/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ We dropped some merch! Use TMS for 10% off. Here is the link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://youknowclothing.com/search?q=tms⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Thank you to the team at Chemist Warehouse for helping us keep the lights on, here at The Morning Shift... ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.chemistwarehouse.co.nz/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 00:00 - INTRO 2:44 - CHECK IN (WORLD CUP FEVER) 11:52 - DAILY BREAD 19:30 - SHIFTERS ASK, WE ANSWER 38:03 - SPEIGHTS MEN'S DEN 44:19 - OUTRO Learn more about your ad choices. Visit megaphone.fm/adchoices

In this Review series episode, Blood associate editor Dr. Diane Krause interviews contributing authors from the Review Series on Clonal tracking in Hematopoiesis published in volume 147 issue 23 of Blood. Dr. Alejo E. Rodriguez-Fraticelli speaks to the development of his paper, "Clonal tracing of blood stem cells across mouse and human lifespans”, which provides a detailed overview of the experimental approaches that make clonal analysis possible, and which approaches are most appropriate to use to address specific questions. Dr. Shalin H. Naik speaks about how different clonal tracking approaches have been used to address the central question of clonal fate specification of stem and progenitor cells to specific lineages in “The evolution of hematopoietic models through a clonal lens”. Finally, Dr. Federico Gaiti speaks about “Methylation-based lineage tracing in cancer”, which takes these ideas into the context of cancer, focusing on how DNA methylation can be used to reconstruct clonal relationships.  

In a special cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of chimeric antigen receptor (CAR) T-cell–related lymphomas developing in the gastrointestinal (GI) tract. The study focused on a particular case involving a 50-year-old patient with relapsed/refractory multiple myeloma who developed T-cell lymphoma after receiving cellular therapy in the seventh-line setting. Listen below or via your favorite podcast platform.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Johnny Mahlangu and Joseph Rocco on their articles published in volume 147 issue 9 of Blood.  Dr. Mahlangu discusses study details and next steps from "Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial" which shows that bleeding was reduced by 93% with subcutaneous marstacimab. Dr. Rocco shares the development behind "CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis", and the insights gained from measuring a new surrogate marker of IFN-γ activity predicting severity and mortality.

Friday - Clark Stinks day! Christa shares Clark Stinks posts with Clark. Submit yours at Clark.com/ClarkStinks.    Also, while many of us use fitness trackers to count steps or monitor sleep, the latest data shows some of these devices are evolving into genuine lifesavers. Clark has worn a Garmin for twenty years and a Samsung smartwatch, but the Oura Ring has truly impressed him and for good reason, as new findings indicate.   Clark Stinks: Segments 1 & 2 Oura Reports: Segment 3 Ask Clark: Segment 4 Mentioned on the show: Is Turo Legit? 5 Things To Know Before You Use It 5 of Clark Howard's Most Extreme Frugal Hacks What Is Umbrella Insurance and Do You Need It? - Clark Howard The Insurance Policies You Need (and Some You Don't) What Age Are Americans Actually Starting Social Security? Term Life vs. Whole Life Insurance: Understanding the Difference Oura Ring Helps Uncover 'Multiple Cases of Lymphoma,' Says Its Chief Medical Officer Axios: Finish Line: The quiet rise of "prescribing connection" 4 Ways To Stop Junk Mail - Clark Howard How To Choose the Best Charities for Your Donations - Clark Howard Memorial Day 2026: Facts, Meaning & Traditions Clark.com resources: Episode transcripts Community.Clark.com  /  Ask Clark Clark.com daily money newsletter Consumer Action Center Free Helpline: 636-492-5275 Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailOn this episode, I sit down with Jules Peters, the wife of the front man of The Alarm, the late Mike Peters. We discuss their incredible love affair, his long battle with cancer, The Alarm's new album, Transformation, and more.****"Mike lived a life of beauty and never gave up right to the very end,” says Jules Peters, bandmate and wife of the late Mike Peters of THE ALARM who passed away on April 29, 2025. Following a fearlessly valiant 31-year battle with cancer, his monumental legacy continues with the release of TRANSFORMATION on May 29, 2026 on Twenty First Century Recordings/Virgin Music Group. Its latest single, “Live Today” premieres now via Consequence.Filmed just days before Mike underwent the innovative CAR-T treatment with hopes of eradicating Richter's Syndrome, an aggressive form of lymphoma, “Live Today” is Mike's final video. “As the sun rose, watching Mike perform this song with so much optimism and hope will live with me forever,” said Jules as she looks back. “It was a bittersweet day for me as we filmed this incredible joyous film on the beach in the North of England. After filming concluded, we climbed onto the tour bus and drove straight to the Christie Hospital in Manchester, U.K.. We were full of determination that the pioneering CAR-T would save Mike's life but, at the same time, I was personally terrified as I couldn't shake off a feeling that cancer had finally caught up with us both.”Diagnosed with lymphoma in 1995 and later with chronic lymphocytic leukemia, Peters refused to let his illness silence him. Instead, he turned his fight into a mission to help others.Alongside his wife Jules, he co-founded Love Hope Strength, a music-driven cancer charity that revolutionized awareness and action around stem cell donation that continues beyond his passing. Through its innovative “Get On The List” campaigns—often hosted at rock concerts and even atop mountains—the charity has added over 400,000 people to the global stem cell registry and helped secure thousands of potential life-saving matches for patients worldwide. While this may seem like the final chapter for The Alarm, Transformation promises that the legacy of The Alarm will transform into something larger. While Mike has gone out in a blaze of glory, his love, hope and strength continues on. Echoing the title of the new single, Jules concludes, “Mike and the spirit of The Alarm will ‘Live Today,' forever more. I invite you all to blast Transformation out loud. Imagine Mike in the room with you. Transformation is his battle cry, his resilient love of life. Right to the very end, Mike believed that he was going to live, to be totally free. My last memory is driving him open top along the North Wales coast road, playing Transformation at maximum volume. He was so happy. So full of life. Playing his air drums, bass guitar, already imagining himself on his next world tour. So keep that positive spirit moving forwards. Imagine him as you all knew him best, striding out on to that stage, changing lives one concert at a time. This is an album of hope and a passionate celebration of a life well lived. Please do not be sad. Mike wouldn't want that. He was so proud of this album and had the best time recording it during the last six months of his life. Blast it out loud like Mike did. Play along to the track list and most of all, be happy that we all had Mike in our lives and continue to do so. The music of Mike and The Alarm will always keep us strong”.****If you would like to contact the show Dauna@betertopodcast.comFollow us on Social MediaYouTube: https://www.youtube.com/channel/UCX0ETs2wpOHbCuhUNr0XFTw?view_as=subscriberInstagram: https://www.instagram.com/author_d.m.needom/Facebook: https://www.facebook.com/bettertopodcastwithdmneedomSupport the podcast here: https://www.patreon.com/bettertopodcastwithdmneedom©2026 Better To...Podcast with D. M.NeedomSupport the show

 In this episode, Blood deputy editor Dr. Helen Heslop interviews contributing  authors from the Blood review series on hemophagocytic lymphohistiocytosis. Drs. Nancy Berliner and Joanne Hsu join to provide insight on their paper, “Hemophagocytic lymphohistiocytosis in adults” discussing the importance of prompt diagnosis and treatment in this high-mortality disorder, and highlight emerging agents designed to modulate disease progression. Drs. Carl Allen and Bethany Verkamp reimagine diagnostic criteria through a threshold model in “Pediatric hemophagocytic lyphohistiocytosis: current conceptualization, diagnosis, and treatment”, in order to provide individualized therapies with the goal of addressing the combined influence of genetic susceptibility and environmental triggers.

What happens when a medical doctor trained in oncology becomes the cancer patient and then transforms into a primary caregiver for his own father? In this moving continuation of our conversation with clinician, survivor, and care partner Dr. Achim, we dive into the profound emotional architecture of navigating a cancer diagnosis. Dr. Achim opens up about the vast difference between his first experience as a helpless care partner for his father's prostate cancer in 2010, and his recent role guiding his 85-year-old father through aggressive lymphoma and groundbreaking CAR T-cell therapy.Samira and Dr. Achim explore a topic rarely discussed openly in the oncology world: the long, arduous journey of rebuilding trust in your body after it feels like it has completely betrayed you. Dr. Achim shares how shifting from anger to radical self-love and mastering the art of strict presence—learning to live purely in the current moment—became his ultimate armor against the paralyzing fear of cancer recurrence. Whether you are a patient looking for tools to manage treatment intervals, a male patient looking for permission to voice your fears, or a caregiver trying to balance medical advocacy with emotional support, this episode offers an essential roadmap for finding steady footing when your world is turned upside down.Chapter Codes:00:00 Grounding in the Present Moment00:44 Dr. Achim's Transition From Patient to Caregiver02:15 The Reality of Being a Cancer Care Partner06:46 Navigating Aggressive Lymphoma & CAR T-Cell Therapy09:57 Healing the Feeling of "Body Betrayal"13:49 Mind-Body Visualizations During the Treatment Time Gap15:36 Overcoming the Fear of Cancer Recurrence19:33 Mental Health Stigmas for Male Cancer Patients25:25 Life with No Evidence of Disease (NED)Key Takeaways from This Episode:The Caregiver Shift: Why true caregiving isn't about having all the answers or trying to "fix" the disease; it is about steady, radical presence and holding a hand through the confusion.The "Betrayal" of the Body:Understanding the mental shift required to stop treating your body like an enemy and realizing that it is still actively fighting for you.The Power of Visualizations:How Dr. Achim used a 5-day Carl Simonton method seminar to train his mind during the critical "time gap" between diagnosis and treatment.Connect with Manta Cares & Patient from Hell:Learn more about our mission: Manta Cares WebsiteDiscover your personal cancer roadmap: Patient from Hell Podcast HubSubscribe, rate, and review on Apple Podcasts, Spotify, and YouTube!Disclaimer: This podcast, show notes, and newsletter are for general informational purposes only and do not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. The use of information on this podcast or any materials linked from it is at the user's own risk. The opinions of the speakers are their own and do not represent the organizations they are affiliated with, nor do they reflect the opinions of Manta Cares Inc. or its sponsors.

Today's guest is Carmen Monge, Hodgkin's Lymphoma survivor, researcher, and patient advocate working at the intersection of lived experience, research, and equity in cancer care, especially across different global healthcare systems.Carmen is the founder of MANO Beyond Cancer, a global initiative exploring survivorship through qualitative research, where she had conducted interviews with survivors from more than 60 countries. She also works as a researcher and patient advocate with Youth Cancer Europe. And the author of CAN-CAN, a children's book series designed to help explain the cancer journey, from diagnosis to life after treatment, in a holistic and accessible way.We talk about hope, cancer research, cultural differences and disparities in cancer care, the challenges of getting treatment is another country from your homeland, common threads among survivors globally, and so much more!!!Resources:Carmen's YouTube channel: https://www.youtube.com/@MANObeyondcancerCarmen's Instagram: https://www.instagram.com/mano_beyondcancer/Carmen's contact info: https://linktr.ee/CarmenMongeFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Reuben Kapur and Robert Campbell on their latest articles published in Blood. This episode highlights two groundbreaking studies exploring how inflammation drives serious blood and immune-related diseases. In the first interview, Dr. Kapur discusses how inflammatory bowel disease (IBD) can both promote and worsen clonal hematopoiesis of indeterminate potential (CHIP), with large-scale human data and mouse models identifying REF1 as a key mediator and potential therapeutic target. The second segment features Dr. Campbell, who explains how heme released during malaria infection activates platelet mTOR signaling, intensifying cerebral malaria and suggesting new avenues for platelet-targeted treatments. Together, the conversations reveal how inflammatory pathways and immune signaling contribute to disease progression while opening the door to novel precision therapies. 

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Link Up w/The Morning Sickness Digitally All Over:Instagram: @hms_98_official, @bosskupd, @bretvesely, @dickToledoX/Twitter: @HMSon98, @DickToledo, @bretveselyFacebook: @HMSKUPDYouTube: @hmspodcast9320, @98kupdRequest/Call in/Wakeup Song line:(IN AZ) 602.585.9800More HMS: holmbergpodcast.com, 98kupd.comEmail: dtoledo@98kupd.com, bvesely@98kupd.com, bbogen@98kupd.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BWH865. CME/MOC/AAPA/IPCE credit will be available until May 5, 2027.Raising the CAP on Lymphoma Care: Community–Aligned Principles for Integrating CELMoDs Into Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BWH865. CME/MOC/AAPA/IPCE credit will be available until May 5, 2027.Raising the CAP on Lymphoma Care: Community–Aligned Principles for Integrating CELMoDs Into Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

Would like like to share feedback on this podcast? Or suggest another topic for us to explore? Click here, or email us at DocTalk@medstar.netOn this DocTalk episode, we chat with Dr. Joseph Roswarski, the lymphoma/leukemia attending at MedStar Georgetown University Hospital and the Georgetown Lombardi Comprehensive Cancer Center. Dr. Roswarski's medical career includes clinical care and research in hematologic malignancies, particularly lymphoma and multiple myeloma. For an interview with Dr. Joseph Roswarski, or for more information about this podcast, contact MedStar Georgetown University Hospital Manager Media Relations, Ryan.M.Miller2@Medstar.net. Learn more about Dr. Roswarski.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BWH865. CME/MOC/AAPA/IPCE credit will be available until May 5, 2027.Raising the CAP on Lymphoma Care: Community–Aligned Principles for Integrating CELMoDs Into Real-World Practice In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

The U.S. Food and Drug Administration, or FDA, has had a busy first quarter…

The U.S. Food and Drug Administration, or FDA, has had a busy first quarter of 2026 approving medications for the animals that we care so much about. In early March—and...

In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Alexis Thompson, former ASH president, on her latest article published in Blood. Dr. Thompson discusses "Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia." She explains transfusion-dependent β-thalassemia (TDT) requires rigorous, lifelong transfusion therapy and iron chelation to manage iron overload. Dr. Kwiatkowski and colleagues discuss the long-term efficacy and safety of this gene therapy in 63 patients with TDT, documenting sustained transfusion independence for up to 10 years and a safety profile consistent with that of myeloablative autologous transplantation.

Ep. 204 - In this powerful episode, Kimberly sits down with Charles Porter, a man of "many talents and mysteries." From his dual citizenship and elite football career at Duke University to a 17-year battle with Stage IV Hodgkin's Lymphoma, Charles shares a masterclass in resilience, the power of brotherhood, and a concept he calls "brainwashing yourself for greatness." Chapter Timestamps: 0:44 - How Childhood Trauma Becomes a Gift 2:12 - Prep School: Exposure to a Different World 3:23 - Football at Duke University & The Power of Teamwork 4:44 - Why I Moved to Hollywood with No Plan 9:32 - Beg, Borrow and Deal: My Start in Reality TV 12:49 - The Bond of Brotherhood: "We Go Hard for Each Other" 16:04 - Pouring Champagne for Eddie Murphy & Celebrity Insight 19:13 - The Ari Emanuel Story: Hanging Up on a Power Agent 21:14 - The Diagnosis: Stage 4 Cancer at Age 30 23:44 - The Essence of Self: Stripped of Physical Identity 26:15 - Brainwashing Yourself for Greatness 28:47 - Parenting Through Chronic Illness 32:13 - The Power of All-In Boundaries 35:32 - Using Stoicism & Visualization to Heal 38:43 - Facing Sepsis: Protecting Your Mental Space 43:03 - Handling Mischaracterization & Character Assassination 45:33 - Charles's "Must-Read" Book Recommendations Follow Charles on Instagram: https://www.instagram.com/cfpgram/ And Black Bench Productions: https://www.instagram.com/p/DPAOvZAEgK2/?img_index=1 Follow Kimberly on Instagram: https://www.instagram.com/kimberlylovi/ Subscribe on YouTube Here:  ⁨https://www.youtube.com/@iconicnationmedia

"I knew the diagnosis, the prognosis, and the five-year survival rates. And for the first time, knowing more didn't help, it made it worse."In this powerful episode of The Patient From Hell, host Samira sits down with Dr. Achim Zinggrebe, a German physician and pharmaceutical oncology expert who found himself on the other side of the stethoscope. After years of treating cancer and developing oncology drugs, Dr. Achim discovered fist-sized lymph nodes on his own MRI, leading to a diagnosis of advanced lymphoma with a 1-to-2-year survival outlook.Dr. Achim shares a raw, clinical, and deeply personal look at the "curse of knowledge" that comes when a doctor becomes the patient. We dive into the "mirror moment" that changed his trajectory, the scientific proof behind integrative therapies like meditation, and why the current medical system often fails to address the "mind and soul" of the person behind the pathology.In this episode, we discuss:The surreal experience of reading your own terminal cancer scans.Why "Dr. Google" is a universal trap, even for medical experts.The transition from conventional oncology to an integrative "Body, Mind, and Soul" approach.The "Mirror Moment": How to start fighting for yourself instead of everyone else.Crucial advice for clinicians on empathy, silence, and treating the human, not just the lab results.Guest Bio:Dr. Achim Zinggrebe is a physician, cancer survivor, and family member of a cancer patient. He works at the intersection of medicine, lived experience, and human reality.Having seen cancer from all three perspectives, his work focuses on helping people find clarity, inner stability, and direction in a time that often feels uncertain. He is the author of Rise and Thrive Above Cancer and the Rise and Thrive Journal, and the creator of a structured pathway that supports people during and beyond treatment in a grounded and honest way.Dr. Achim Zinggrebe joins us from Southern Germany to share how he transformed a devastating prognosis into a mission to provide a "shortcut" for other patients through his upcoming book and advocacy.Chapter Codes00:00 - The MRI That Changed Everything00:44 - Introducing Dr. Achim: Physician, Survivor, & Caregiver02:02 - From Paramedic to Oncology: A Career Built on Helping04:01 - The Diagnosis: Advanced Lymphoma05:30 - Ignoring the Signs: Why We Put Ourselves Last06:07 - The Curse of Knowledge: Why Knowing the Survival Rates is a Burden08:04 - Seeking Hope in a 2-Year Prognosis10:49 - What Medical School Never Taught Me About Being a Patient12:37 - The Missing Piece in Oncology: Body, Mind, and Soul15:12 - The Mirror Moment: Redefining the Role of Medicine18:30 - Rebuilding Your Identity After a Diagnosis22:51 - The Science of Integrative Medicine & Meditation26:53 - Advice to Clinicians: Listen More, Talk Less28:47 - The System vs. The Human BeingSupport the Podcast:If you found this story inspiring, please Like, Subscribe, and hit the Notification Bell. Sharing these stories helps break the stigma surrounding lung cancer and provides a community for those in the fight.#LungCancer #PatientStories #DoubleLungTransplant #CancerAdvocacy #PatientFromHell #ManticareDisclaimer:This podcast, show notes, and newsletter are for general informational purposes only and do not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice; no doctor-patient relationship is formed. The use of information on this podcast or any materials linked from this blog is at the user's own risk. The opinions of the speakers are their own and do not represent the opinions of organizations they are affiliated with, nor do they reflect the opinions of Manta Cares Inc. or Manta Cares' sponsors.

One heavy squat at 400 pounds was all Kalil Sherrod needed to know the poison hadn't won. Seven weeks before this recording, Kalil walked into elitefts HQ to hit his first major milestone since a brutal cancer diagnosis. That moment bridged the gap between his life as an elite performance coach and his reality as a survivor. Through two stem cell transplants and multiple rounds of high-intensity chemotherapy, he developed a conjugate-based survival blueprint—one that reinforces a hard truth: muscle mass is one of the most powerful insurance policies for the human body. Inside the Episode: The 93% Rule: Why maintaining a high performance floor matters more than chasing a peak during a competitive season Conjugate for the Court: Applying Westside methodology to basketball players without sacrificing vertical jump or shooting touch Training Through the Storm: How Kalil adjusted his training split during "ICE" chemotherapy to preserve lean tissue The Youth Development Gap: Why the loss of PE and martial arts is producing more fragile athletes—and how to reverse it The IV Protocol: A critical hydration strategy often overlooked during medical treatment Meet the Guest: Kalil Sherrod is a high-performance coach, author, and founder of Revenants Coaching. A former Division II basketball player, he serves as a Sports Performance Coach for the Thailand Titans and works with athletes at The Spot Athletics. He is the author of The Basketball Player's Training Guide and co-author of the elitefts eBook Mastering Conjugate Programming for Athletes. After surviving Hodgkin's Lymphoma, Kalil has dedicated his work to helping athletes and survivors use strength as a foundation for resilience. Connect with Kalil Sherrod: Instagram: https://www.instagram.com/kalil_sherrod YouTube: https://www.youtube.com/@kalilsherrod4882 Linktree: https://linktr.ee/kalilsherrod The Get Clean Podcast: https://podcasters.spotify.com/pod/show/kalil-sherrod7 The Spot Athletics: https://www.thespotathletics.com Revenants Coaching: https://linktr.ee/kalilsherro Become an elitefts Channel Member: Get early access to Dave Tate's Table Talk and more: @eliteftsofficial Support Dave Tate's Table Talk: FULL Crew Access: https://www.elitefts.com/join-the-crew Limited Edition Apparel: https://www.elitefts.com/shop/apparel/limited-edition.html Programs & More: https://www.elitefts.com/shop/dave-tate-s-table-talk-crew.html TYAO Application: https://www.elitefts.com/dave-tate-s-tyao-application Best-Selling elitefts Products: Pro Resistance Bands: https://www.elitefts.com/shop/bands.html Specialty Barbells: https://www.elitefts.com/shop/bars-weights/specialty-bars.html Wraps, Straps, Sleeves: https://www.elitefts.com/shop/power-gear.html Sponsors: Get an extra 10% OFF at elitefts (CODE: TABLE TALK): https://www.elitefts.com/ Get 10% OFF Marek Health Labs (CODE: TABLETALK): https://marekhealth.com/tabletalk Free 8-count LMNT Sample Pack: http://www.drinklmnt.com/tabletalk Support Massenomics: https://www.massenomics.com/ Save 20% on MASS Research Review (CODE: ELITEFTS20): https://massresearchreview.com/ Get 10% OFF RP Hypertrophy App (CODE: TABLE TALK): https://rpstrength.com/pages/hypertrophy-app

One heavy squat at 400 lbs was the only signal Kalil Sherrod needed to know the poison hadn't won yet. Seven weeks before recording this episode, Kalil walked into elitefts HQ to hit his first heavy milestone since a grueling cancer diagnosis—a moment that bridged the gap between his life as an elite performance coach and his reality as a survivor. Through two stem cell transplants and rounds of high-intensity chemo, he has refined a conjugate-based survival blueprint that proves muscle mass is the ultimate insurance policy for the human immune system. INSIDE THE EPISODE: The 93% Rule: Why maintaining a high performance floor is more critical than chasing a ceiling during a competitive season. Conjugate for the Court: How to apply Westside methodology to basketball players without sacrificing their vertical or shooting touch. Training Through the Storm: The specific adjustments Kalil made to his training split while undergoing "ICE" chemotherapy to preserve lean tissue. The Youth Developmental Gap: Why the loss of traditional PE and martial arts is creating a generation of fragile athletes and how to fix it. The IV Protocol: A critical, overlooked hydration tip for anyone navigating medical treatments that often gets ignored by hospital staff. MEET THE GUEST: Kalil Sherrod is a high-performance coach, author, and the founder of Revenants Coaching. A former DII basketball player, he currently serves as the Sports Performance Coach for the Thailand Titans professional basketball organization and coaches at The Spot Athletics. Kalil is the author of The Basketball Player's Training Guide and co-author of the elitefts eBook Mastering Conjugate Programming for Athletes. After surviving Hodgkin's Lymphoma, he has dedicated his work to helping athletes and fellow survivors use strength as a tool for radical resilience. CONNECT WITH KALIL SHERROD: Instagram: https://www.instagram.com/kalil_sherrod YouTube: https://www.youtube.com/@kalilsherrod4882 Linktree: https://linktr.ee/kalilsherrod The Get Clean Podcast: https://spotify.com/0 The Spot Athletics: https://www.thespotathletics.com Revenants Coaching: https://linktr.ee/kalilsherro SUPPORT DAVE TATE'S TABLE TALK: FULL Crew Access: https://www.elitefts.com/join-the-crew Limited Edition Apparel: https://www.elitefts.com/shop/apparel/limited-edition.html Programs & More: https://www.elitefts.com/shop/dave-tate-s-table-talk-crew.html TYAO Application: https://www.elitefts.com/dave-tate-s-tyao-application ELITEFTS GEAR: Pro Resistance Training Bands: https://www.elitefts.com/shop/bands.html Specialty Barbells: https://www.elitefts.com/shop/bars-weights/specialty-bars.html Wraps, Straps, Sleeves: https://www.elitefts.com/shop/power-gear.html SPONSORS: elitefts: (CODE: TABLE TALK) https://www.elitefts.com/ Marek Health Labs: (CODE: TABLETALK) https://marekhealth.com/tabletalk LMNT: (Free Sample Pack) http://www.drinklmnt.com/tabletalk Massenomics: https://www.massenomics.com/ MASS Research Review: (CODE: ELITEFTS20) https://massresearchreview.com/ RP Hypertrophy App: (CODE: TABLE TALK) https://rpstrength.com/pages/hypertrophy-app

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Francesco Forconi and Bin Guo on their latest articles published in Blood. Dr. Guo shares insights from "Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming". The findings establish biomechanical regulation as an important determinant of stem cell identity and reveal new strategies for engineering stem cells with enhanced regenerative capacity. Then, Dr. Forconi discusses "DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival". Persistent, low-level BCR engagement by DC-SIGN enables FL tissue retention and survival while avoiding the deleterious proapoptotic consequences of stronger, conventional antigen-driven BCR signaling. These findings help explain how FL cells exploit their microenvironmental niche.

A pivotal JAMA randomized trial introduces an epigenetic twist to frontline therapy in high-risk DLBCL. Adding tucidinostat (HDAC inhibitor) to R-CHOP improved event-free survival (HR 0.72, P=0.02) and increased complete response rates (73% vs 62%) in MYC/BCL2 double-expressor lymphoma. Toxicity was higher but manageable.   A quiet but meaningful shift—targeting biology, not just burden.   #DLBCL #Lymphoma #Oncology #PrecisionMedicine #JAMA #ClinicalTrials

In this week's episode, Blood podcast editor Laurie Sehn interviews Drs. Edward Cliff on his latest research published in volume 147 issue 14 of Blood. Dr. Cliff discusses "Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries" which maps the mismatch between innovation and implementation across high-income and selected-upper-middle-income countries for US Food and Drug Administration–approved products and indications. 

It's Wish Week here on Newstalk, and we are highlighting the incredible work Make-A-Wish does in helping create life-changing wishes for children with critical illnesses…Seán is joined by Isabelle McCarthy, who was diagnosed with Hodgkin's Lymphoma, and her dad Brendan to discuss the wish she had been granted…Let's make 2026 the biggest Wish Week yet! Every cent matters. Donate online at makeawish.ie/donate.

In this week's episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly important conversation that is so important in the current treatment landscape and one that you don't want to miss.If you haven't done so already, be sure to check out our CAR T episode.Content:- What are bispecific T-cell engagers? - How are they different than CAR T? - A discussion of the pivotal MajesTEC-3 trial (NEJM 2025) - What are key side effects?- How to sequence CAR T vs. bispecific T-cell engagers? ** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

When you're facing a diagnosis, a fear, or a season of waiting, it's easy to feel overwhelmed by the unknown. In today's episode, Tommy Jennings shares a powerful testimony of courage, peace, and unshakable faith as he battles Hodgkin's Lymphoma — a fight he's been in for six years. Tommy's story is raw, honest, and deeply hope‑filled. After exhausting every treatment option, he now lives in the tension of uncertainty — yet his confidence in Jesus has only grown stronger. His words, "Either way it goes, I win," will challenge and inspire you to trust God in your own battles. In this conversation, we talk about: What faith looks like when the prognosis isn't what you hoped for How to cling to God when you're waiting for answers Finding peace in the middle of fear, suffering, and the unknown The hope of Jesus when life doesn't make sense Why Tommy refuses to feel sorry for himself — and how his perspective can reshape your own Whether you're walking through illness, fear, or a difficult season, this episode will remind you that God is near, God is faithful, and God is still writing your story.  Watch on YouTube: Finding Hope in the Unknown: Tommy Jennings' Fight with Cancer Ep. 164 Contact Carol at CarolRoper.org/contact

In this week's episode, we take a practical dive into the relapsed/refractory myeloma space, with a focus on the role of CAR T therapy for relapsed/refractory. In our next episode, we will continue on with a discussion on bispecific agents! This is a conversation that is so important in the current treatment landscape and one that you don't want to miss. Content:- What are treatment options for patients with relapsed/refractory multiple myeloma (R/R MM)? - What is CAR T therapy? And what role does it play in R/R MM?- What are the available options for CAR T for R/R MM?- What are the toxicity profiles of available agents? - How to choose between the options?** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube